Immuno-oncology Iteos Therapeutics advances anti-TREM2 monoclonal antibody toward IND filing Jan. 13, 2025 Iteos Therapeutics Inc. is advancing EOS-215, an anti-TREM2 monoclonal antibody, toward an IND filing.Read More